Arbutus Biopharma Operating Margin vs. Cash Per Share

ABUS Stock  USD 3.76  0.08  2.17%   
Based on the key profitability measurements obtained from Arbutus Biopharma's financial statements, Arbutus Biopharma Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Arbutus Biopharma's ability to earn profits and add value for shareholders.

Arbutus Biopharma Operating Profit Margin

(4.52)

At this time, Arbutus Biopharma's Days Sales Outstanding is comparatively stable compared to the past year. EV To Sales is likely to gain to 23.00 in 2024, whereas Operating Cash Flow Sales Ratio is likely to drop (4.97) in 2024. At this time, Arbutus Biopharma's Total Other Income Expense Net is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 4.7 M in 2024, despite the fact that Accumulated Other Comprehensive Income is likely to grow to (46 M).
For Arbutus Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arbutus Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arbutus Biopharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arbutus Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arbutus Biopharma Corp over time as well as its relative position and ranking within its peers.
  

Arbutus Biopharma's Revenue Breakdown by Earning Segment

Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.43)
Revenue Per Share
0.037
Quarterly Revenue Growth
(0.71)
Return On Assets
(0.33)
Return On Equity
(0.68)
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Arbutus Biopharma Corp Cash Per Share vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Arbutus Biopharma's current stock value. Our valuation model uses many indicators to compare Arbutus Biopharma value to that of its competitors to determine the firm's financial worth.
Arbutus Biopharma Corp is rated fourth in operating margin category among its peers. It also is rated fourth in cash per share category among its peers . At this time, Arbutus Biopharma's Operating Profit Margin is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arbutus Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Arbutus Cash Per Share vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Arbutus Biopharma

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(13.05) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Arbutus Biopharma

Cash Per Share

 = 

Total Cash

Average Shares

 = 
1.00 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Arbutus Cash Per Share Comparison

Arbutus Biopharma is currently under evaluation in cash per share category among its peers.

Arbutus Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Arbutus Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Arbutus Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Arbutus Biopharma's change in net profit over the period of time. It can combine multiple indicators of Arbutus Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-48.4 M-46 M
Operating Income-78.1 M-82 M
Net Loss-72.8 M-76.5 M
Net Loss-75.5 M-71.7 M
Income Before Tax-72.8 M-76.5 M
Total Other Income Expense Net5.3 M5.5 M
Net Loss-62.5 M-65.6 M
Income Tax Expense(1.00)(1.05)
Non Operating Income Net Other2.5 M2.4 M
Interest Income5.2 M3.7 M
Net Interest Income4.4 M4.7 M
Change To NetincomeM1.9 M
Net Loss(0.44)(0.46)
Income Quality 1.18  0.83 
Net Income Per E B T 0.96  0.76 

Arbutus Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Arbutus Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Arbutus Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Arbutus Biopharma's important profitability drivers and their relationship over time.

Use Arbutus Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.

Arbutus Biopharma Pair Trading

Arbutus Biopharma Corp Pair Trading Analysis

The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Arbutus Biopharma position

In addition to having Arbutus Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corporate Bonds Funds Thematic Idea Now

Corporate Bonds Funds
Corporate Bonds Funds Theme
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.